Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CRISPR Therapeutics AG is a biotechnology business based in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. CRISPR Therapeutics employs 410 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$124.52|
|52-week range||$79.31 - $220.20|
|50-day moving average||$123.97|
|200-day moving average||$124.06|
|Wall St. target price||$162.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-13)||5.53%|
|1 month (2021-08-20)||6.23%|
|3 months (2021-06-18)||-2.59%|
|6 months (2021-03-19)||-3.93%|
|1 year (2020-09-18)||44.96%|
|2 years (2019-09-20)||157.65%|
|3 years (2018-09-20)||154.17%|
|5 years (2016-09-16)||N/A|
Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CRISPR Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, CRISPR Therapeutics shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $459.2 million.
The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$901.8 million|
|Operating margin TTM||49.67%|
|Gross profit TTM||$-266,227,000|
|Return on assets TTM||14.19%|
|Return on equity TTM||25.41%|
|Market capitalisation||$9.5 billion|
TTM: trailing 12 months
There are currently 3.0 million CRISPR Therapeutics shares held short by investors – that's known as CRISPR Therapeutics's "short interest". This figure is 0.8% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting CRISPR Therapeutics shares can be evaluated.
CRISPR Therapeutics's "short interest ratio" (SIR) is the quantity of CRISPR Therapeutics shares currently shorted divided by the average quantity of CRISPR Therapeutics shares traded daily (recently around 1.1 million). CRISPR Therapeutics's SIR currently stands at 2.74. In other words for every 100,000 CRISPR Therapeutics shares traded daily on the market, roughly 2740 shares are currently held short.
However CRISPR Therapeutics's short interest can also be evaluated against the total number of CRISPR Therapeutics shares, or, against the total number of tradable CRISPR Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CRISPR Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 CRISPR Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0447% of the tradable shares (for every 100,000 tradable CRISPR Therapeutics shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CRISPR Therapeutics.
Find out more about how you can short CRISPR Therapeutics stock.
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as $79.31 up to $220.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.2344. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.